Strong Revenue Growth Across the Business
Revenue increased 8.4% YoY to $4.15B in Q1 FY2026 (from $3.83B in Q1 FY2025), reflecting continued demand for IQVIA's clinical research, technology, and data analytics services in the life sciences sector.
IQVIA HOLDINGS INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: IQVIA (IQV) delivered solid Q1 FY2026 results with revenue growing 8.4% YoY to $4.15B and net income rising 10.0% to $274M, though operating margin compressed slightly to 12.4% amid elevated debt levels and aggressive share buybacks.
Drawn from management commentary in the Q1 2026 10-Q:
Revenue increased 8.4% YoY to $4.15B in Q1 FY2026 (from $3.83B in Q1 FY2025), reflecting continued demand for IQVIA's clinical research, technology, and data analytics services in the life sciences sector.
Net income grew 10.0% YoY to $274M, while diluted EPS surged 15.0% to $1.61 (from $1.40), with EPS growth outpacing net income growth due to share count reduction from aggressive buybacks of $552M in the quarter.
Operating margin declined modestly to 12.4% from 13.0% in the prior-year period, even as SG&A expenses fell 1.2% YoY to $502M, suggesting higher cost of revenues or increased D&A (up 8.7% to $288M) weighed on profitability.
Revenue
$4.15B
++8.41% YoY
EPS (Basic)
$1.63
++14.79% YoY
Operating Income
$514M
++3.63% YoY
Add IQV to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.